BlueStone Venture Partners

GT Medical Technologies develops and manufactures a novel medical device for treating brain tumors. Its flagship product, GammaTile™, combines a conformable collagen matrix with brachytherapy seeds to deliver targeted radiation therapy, potentially revolutionizing treatment for over 176,000 patients annually in the U.S. The company's focus is improving patient outcomes and quality of life.

Based in Boston's biotech hub, Elucid improves cardiovascular diagnostic imaging via machine learning. Its flagship product, ElucidVivo, is the first FDA-cleared software for evaluating plaque vulnerability from a single CT scan to inform risk assessment and treatment selection.

Akadeum Life Sciences develops bioseparation products that facilitate the removal of target cells from biological samples using microscopic micro-bubbles. Its products enable medical practitioners to efficiently perform downstream testing and analysis.

Based in Boston's biotech hub, Elucid improves cardiovascular diagnostic imaging via machine learning. Its flagship product, ElucidVivo, is the first FDA-cleared software for evaluating plaque vulnerability from a single CT scan to inform risk assessment and treatment selection.

GT Medical Technologies develops and manufactures a novel medical device for treating brain tumors. Its flagship product, GammaTile™, combines a conformable collagen matrix with brachytherapy seeds to deliver targeted radiation therapy, potentially revolutionizing treatment for over 176,000 patients annually in the U.S. The company's focus is improving patient outcomes and quality of life.

Founded in 2017, Pyx Health is a healthcare technology company based in Tucson, Arizona. It develops a mobile solution that connects with members outside traditional care settings to reduce loneliness and social isolation. The platform combines artificial intelligence and human interventions for timely health interventions, addressing social determinants of health.

Paradigm Diagnostics specializes in advanced diagnostics technology for personalized cancer treatment. Using Next-Gen Sequencing and other biomarker analysis methods, the company provides detailed information about a patient's genomic and proteomic landscape, identifying specific characteristics of their tumor. This data is used to tailor treatment plans by matching potential therapies to the unique profile of each patient's cancer, thereby enhancing the effectiveness of clinical trials and improving outcomes for cancer patients.

GT Medical Technologies develops and manufactures a novel medical device for treating brain tumors. Its flagship product, GammaTile™, combines a conformable collagen matrix with brachytherapy seeds to deliver targeted radiation therapy, potentially revolutionizing treatment for over 176,000 patients annually in the U.S. The company's focus is improving patient outcomes and quality of life.

BroadSpot Imaging Corporation focuses on developing diagnostic medical devices for eye care, specifically in the area of retinal imaging. The company employs advanced imaging technologies and compact, cloud-connected electronics to create cost-effective handheld instruments that replace traditional bulky and expensive diagnostic tools. By integrating AI and machine learning applications, BroadSpot Imaging aims to enhance the efficiency and accessibility of eye care services. Their innovations are designed to meet the growing demand for high-quality diagnostics, particularly as the population ages, allowing eye care professionals to serve more patients effectively and affordably across various medical settings.